Please login to the form below

Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

J&J splashes $750m on anti-inflammatory drug bermekimab

J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing

Latest news

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.
Janssen files Tremfya for psoriatic arthritis in Europe

First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three
CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.
Litigation concerns threaten to overshadow solid quarter at J&J

Growth for immunology therapy Stelara (ustekinumab) and blood cancer drugs Imbruvica (ibrutinib) and Darzalex (daratumumab) – plus Stelara follow-up Tremfya (guselkumab) – outweighed the effect of generic competition to older prostate cancer
J&J's Tremfya filed for approval in US for psoriatic arthritis

Tremfya (guselkumab) is Janssen’s follow-up to IL-23/IL-12 inhibitor blockbuster Stelara (ustekinumab), which has faced competition from rival new treatments across immunology indications. ... AbbVie’s Humira and J&J’s Stelara have remained

More from news
Approximately 15 fully matching, plus 72 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were
Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Back to the future

Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Why are new medicinal products denied reimbursement in France?

Haute Autorité De Sante. 2017. Available at: https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-11/stelara_mc_summary_ct15850.pdf [Accessed 20 December 2018].

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: ...
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...